We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

79 hedge funds and large institutions have $224M invested in Progenics Pharmaceuticals Inc in 2013 Q2 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

96% less call options, than puts

Call options by funds: $81K | Put options by funds: $1.83M

Holders
79
Holders Change
+79
Holders Change %
–
% of All Funds
2.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
79
Increased
–
Reduced
–
Closed
–
Calls
$81K
Puts
$1.83M
Net Calls
-$1.75M
Net Calls Change
-$1.75M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$56M +$56.3M +12,549,790 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$37.9M +$38.2M +8,503,246 New
BBA
3
Baker Bros. Advisors
New York
$18.7M +$18.8M +4,200,000 New
BC
4
Broadfin Capital
New York
$15.6M +$15.7M +3,500,615 New
Tudor Investment Corp
5
Tudor Investment Corp
Connecticut
$10.4M +$10.5M +2,342,388 New
HCMT
6
Highland Capital Management (Texas)
Texas
$9.75M +$9.81M +2,186,853 New
BFA
7
BlackRock Fund Advisors
California
$7.71M +$7.76M +1,729,000 New
BIT
8
BlackRock Institutional Trust
California
$6.66M +$6.7M +1,493,011 New
Wellington Management Group
9
Wellington Management Group
Massachusetts
$5.99M +$6.02M +1,342,204 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$5.61M +$5.64M +1,256,684 New
Morgan Stanley
11
Morgan Stanley
New York
$4.6M +$4.62M +1,030,576 New
Franklin Resources
12
Franklin Resources
California
$3.51M +$3.53M +786,716 New
TCA
13
Taconic Capital Advisors
New York
$3.5M +$3.53M +785,982 New
State Street
14
State Street
Massachusetts
$3.26M +$3.28M +729,968 New
Northern Trust
15
Northern Trust
Illinois
$3.05M +$3.07M +683,353 New
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$2.85M +$2.86M +638,405 New
KCM
17
Kingdon Capital Management
New York
$2.58M +$2.6M +580,000 New
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$2.25M +$2.26M +504,093 New
Deutsche Bank
19
Deutsche Bank
Germany
$1.97M +$1.98M +441,961 New
Citadel Advisors
20
Citadel Advisors
Florida
$1.77M +$1.78M +397,254 New
UOC
21
UBS O'Connor
Illinois
$1.42M +$1.43M +318,191 New
PA
22
Perceptive Advisors
New York
$1.37M +$1.38M +306,650 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.23M +$1.24M +275,232 New
CS
24
Credit Suisse
Switzerland
$1.13M +$1.13M +252,833 New
AQR Capital Management
25
AQR Capital Management
Connecticut
$1.11M +$1.12M +250,000 New
1
2 3 4

PGNX Hedge Fund Activity: Q2 2013 in Review

79 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2013, worth a combined $224M.

Buyers outnumbered sellers: 79 funds opened new PGNX positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.

  • 79 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $224M of Progenics Pharmaceuticals Inc stock for Q2 2013.
  • 79 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2013 and 0 closed out, a net change of +79 holders.

Based on aggregated 13F filings for Q2 2013.